A Review on Current Status and Future Prospectus of Oral Vaccines

References (79)

1. 1 PLGA-based nanoparticles: An overview of biomedical applications [DOI]
2. 2 Regional specialization within the intestinal immune system [DOI]
3. 3 Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies [DOI]
4. 4 Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriers [DOI]
5. 5 Mucosal immunity and vaccines [DOI]
6. 6 Retinoic Acid Imprints Gut-Homing Specificity on T Cells [DOI]
7. 7 Barrier properties of mucus [DOI]
8. 8 The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system [DOI]
9. 9 Mucosal vaccines: the promise and the challenge [DOI]
10. 10 Recent progress in mucosal vaccine development: potential and limitations [DOI]
11. 11 Visual Evidence of Acidic Environment Within Degrading Poly(lactic-co-glycolic acid) (PLGA) Microspheres [DOI]
12. 12 Approaches for enhancing oral bioavailability of peptides and proteins [DOI]
13. 13 Strategies intended to address vaccine hesitancy: Review of published reviews [DOI]
14. 14 Engineering synthetic vaccines using cues from natural immunity [DOI]
15. 15 The intestinal epithelial stem cell [DOI]
16. 16 Preferential Generation of Follicular B Helper T Cells from Foxp3 + T Cells in Gut Peyer's Patches [DOI]
17. 17 Nanotechnology in vaccine delivery [DOI]
18. 18 Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery [DOI]
19. 19 Needle-free vaccine delivery☆ [DOI]
20. 20 Nanoparticles for oral delivery: Targeted nanoparticles with peptidic ligands for oral protein delivery [DOI]
21. 21 Chitosan nanoparticles for oral drug and gene delivery [DOI]
22. 22 Gut instincts: Explorations in intestinal physiology and drug delivery [DOI]
23. 23 Gut instincts: thoughts on intestinal epithelial stem cells [DOI]
24. 24 Hydrogels and Scaffolds for Immunomodulation [DOI]
25. 25 Single Mucosal, but Not Parenteral, Immunization with Recombinant Adenoviral-Based Vaccine Provides Potent Protection from Pulmonary Tuberculosis [DOI]
26. 26 Emerging Trends in Oral Delivery of Peptide and Protein Drugs [DOI]
27. 27 Rationalizing the development of live attenuated virus vaccines [DOI]
28. 28 PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination [DOI]
29. 29 Classification and functions of enteroendocrine cells of the lower gastrointestinal tract [DOI]
30. 30 Vaccine adjuvants: Current challenges and future approaches [DOI]
31. 31 Occupational exposure to needlestick injuries and hepatitis B vaccination coverage among health care workers in Egypt [DOI]
32. 32 Immunology of gut mucosal vaccines [DOI]
33. 33 Keynote review: Intestinal Peyer's patch M cells and oral vaccine targeting [DOI]
34. 34 Bridging the knowledge gaps in vaccine design [DOI]
35. 35 Delivery strategies to enhance oral vaccination against enteric infections [DOI]
36. 36 Vaccines against mucosal infections [DOI]
37. 37 Rotavirus vaccination: a concise review [DOI]
38. 38 Single-injection vaccines: Progress, challenges, and opportunities [DOI]
39. 39 Towards tailored vaccine delivery: Needs, challenges and perspectives [DOI]
40. 40 New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development [DOI]
41. 41 Epidemiology of Poliomyelitis in the United States One Decade after the Last Reported Case of Indigenous Wild Virus-Associated Disease [DOI]
42. 42 The Intangible Value of Vaccination [DOI]
43. 43 Comparative Efficacy of Two, Three, or Four Doses of TY21a Live Oral Typhoid Vaccine in Enteric-Coated Capsules: A Field Trial in an Endemic Area [DOI]
44. 44 Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial [DOI]
45. 45 Delivery systems for penetration enhancement of peptide and protein drugs: design considerations [DOI]
46. 46 Immunoadjuvant capacity of flagellin and mannosamine-coated poly(anhydride) nanoparticles in oral vaccination [DOI]
47. 47 PEG–PLA–PEG block copolymeric nanoparticles for oral immunization against hepatitis B [DOI]
48. 48 Administration strategies for proteins and peptides [DOI]
49. 49 Control of adenovirus acute respiratory disease in U.S. Army trainees.
50. 50 Poly anhydride nanoparticles as adjuvants for mucosal vaccination [DOI]
51. 51 Intestinal epithelial cells: regulators of barrier function and immune homeostasis [DOI]
52. 52 The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo [DOI]
53. 53 Epithelial antimicrobial defence of the skin and intestine [DOI]
54. 54 Survey of the prevalence of immunization non-compliance due to needle fears in children and adults [DOI]
55. 55 The intestinal epithelial stem cell: the mucosal governor [DOI]
56. 56 Physiological Parameters for Oral Delivery and in Vitro Testing [DOI]
57. 57 Vaccine impact: Benefits for human health [DOI]
58. 58 What Role Does the Route of Immunization Play in the Generation of Protective Immunity against Mucosal Pathogens? [DOI]
59. 59 Vaccine technologies: From whole organisms to rationally designed protein assemblies [DOI]
60. 60 Large intestine–targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection [DOI]
61. 61 Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea [DOI]
62. 62 Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination [DOI]
63. 63 Vaccine delivery carriers: Insights and future perspectives [DOI]
64. 64 Subsets of migrating intestinal dendritic cells [DOI]
65. 65 Current management of the gastrointestinal complications of systemic sclerosis [DOI]
66. 66 Perspectives on Mucosal Vaccines: Is Mucosal Tolerance a Barrier? [DOI]
67. 67 Poly(Anhydride) Nanoparticles Act as Active Th1 Adjuvants through Toll-Like Receptor Exploitation [DOI]
68. 68 Oral vaccine delivery [DOI]
69. 69 Digestion of Nucleic Acids Starts in the Stomach [DOI]
70. 70 Food-associated stimuli enhance barrier properties of gastrointestinal mucus [DOI]
71. 71 Is There an Optimal Formulation and Delivery Strategy for Subunit Vaccines? [DOI]
72. 72 Induction of mucosal and systemic immune response by single-dose oral immunization with biodegradable microparticles containing DNA encoding HBsAg [DOI]
73. 73 Formulation, characterization and evaluation of rotavirus encapsulated PLA and PLGA particles for oral vaccination [DOI]
74. 74 Complexation hydrogels as potential carriers in oral vaccine delivery systems [DOI]
75. 75 Polyanhydride Nanovaccines Induce Germinal Center B Cell Formation and Sustained Serum Antibody Responses [DOI]
76. 76 Viral Vaccination Via the Mucosal Routes [DOI]
77. 77 THE COSTS OF INTRODUCING A MALARIA VACCINE THROUGH THE EXPANDED PROGRAM ON IMMUNIZATION IN TANZANIA [DOI]
78. 78 Investigation of 3-D ordered materials with a high adsorption capacity for BSA and their potential application as an oral vaccine adjuvant [DOI]
79. 79 Re-born in the USA: Another cholera vaccine for travellers [DOI]

Cited by 1

Related research

• Epidemiological Profile of HIV among Elderly in Brazil from 2019 to 2023 — shares topic coverage
• Vaccination Coverage Against Human Papillomavirus (HPV) : A Study on Vaccination in the Municipality of Ananindeua, Brazil — shares topic coverage
• Dynamics of Urban Arboviruses Transmitted by Aedes Aegypti in Brazil: Integrative Literature Review — shares topic coverage
• Effect of Communicable Diseases on the Economy: A Panel Data Analysis — shares topic coverage
• A Review on Human Metapneumovirus and Human Bocavirus Associated with Acute Respiratory Tract Infections — shares topic coverage